Radioactive drug plus precise radiation for recurrent prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a powerful radioactive drug (either alpha or beta) combined with precise radiation to treat prostate cancer that has come back in a few spots outside the prostate. It may help men whose cancer is still hormone-sensitive and has not spread widely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have 1 to 5 cancer spots that have returned (not in the prostate itself) and aren't causing symptoms.
- Your testosterone level is above 150 ng/dL (so your cancer isn't castrate-resistant).
- You haven't had hormone therapy or chemotherapy in the last 6 months.
- Your blood counts (white cells, platelets, hemoglobin) and kidney/liver function are within the study's safe range.
- You are 18 or older, can lie flat for treatment, and agree to use effective birth control during and 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of radiation therapy for prostate cancer that has come back or spread to a few places after surgery. The goal is to see which radiation schedule works better with fewer side effects.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
Hear when a new Oligometastatic Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.